This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.

Start Date21 Oct 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06976658

/ RecruitingPhase 2IIT

Evaluating a Novel, Allosteric Glucokinase Activator in Monogenic Diabetes Secondary to Inactivating Glucokinase Mutations: a Randomised, Cross-over Trial

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

Start Date30 Apr 2025

Sponsor / Collaborator

The Chinese University of Hong Kong

NCT06671340

/ Not yet recruitingNot ApplicableIIT

Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.

Start Date02 Apr 2025

Sponsor / Collaborator

The Chinese University of Hong Kong

100 Clinical Results associated with Dorzagliatin

100 Translational Medicine associated with Dorzagliatin

100 Patents (Medical) associated with Dorzagliatin

Literatures (Medical) associated with Dorzagliatin

15 Apr 2026·FASEB JOURNAL

Contrasting Effects of Chronic Glucokinase Activation and Inhibition on Pancreatic Beta‐Cell Function

Article

Author: Alexandra C. Title ; Burcak Yesildag ; Elizabeth Haythorne ; Samuel J. Mullan ; Aerin J. Dumenil ; Alice Elphick ; Matthew Lloyd ; Chantal Rufer ; Frances M. Ashcroft ; Natascia Vedovato

ABSTRACT:

Chronic hyperglycaemia impairs insulin secretion by disrupting beta‐cell metabolism and reducing expression of insulin. These changes are mediated by glucose metabolites downstream of glucokinase. We hypothesized that chronically enhancing glucokinase activity at low glucose would mimic the effects of glucotoxicity and, conversely, that reducing glucokinase activity would prevent the deleterious effects of chronic hyperglycaemia. Human islet microtissues or INS‐1 cells were cultured at low or high glucose for 2 weeks (islets) or 48 h (INS‐1 cells) in the presence or absence of either a glucokinase activator (MK‐0941 or dorzagliatin) or a glucokinase inhibitor (mannoheptulose). We measured changes in glucose‐stimulated insulin secretion, insulin content, glycogen content, gene expression, and oxygen consumption. Chronic glucokinase activation in low‐glucose‐cultured islet microtissues and INS‐1 cells downregulated insulin secretion and content, impaired mitochondrial metabolism, and altered metabolic gene expression, to the same extent as high‐glucose culture. Conversely, reduction of glucokinase activity in high‐glucose‐cultured islet microtissues by mannoheptulose prevented the changes produced by chronic hyperglycaemia. Moreover, the effects of chronic hyperglycaemia on insulin secretion and metabolic gene expression (but not insulin content) were largely reversed by subsequent inhibition of glucokinase. Chronic glucokinase activation in euglycaemia thus mimics the effects of chronic hyperglycaemia, whereas partial inhibition of glucokinase in hyperglycaemia restores normal beta‐cell function. This explains why, in the long term, glucokinase activators are ineffective at controlling glycaemia in type 2 diabetes, and demonstrates that normalizing glucokinase activity can prevent and reverse chronic glucose toxicity.

01 Mar 2026·Cell Reports Medicine

Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia

Article

Author: Sun, Yaoyao ; Yuan, Rui ; Zhu, Yunqing ; Yue, Weihua ; Feng, Xiaoyang ; Lu, Zhe ; Sun, Junyuan ; Yang, Yang ; Kang, Zhewei ; Zhang, Yuyanan ; Yu, Tong ; Zhao, Guorui ; Guo, Jing

Schizophrenia is frequently comorbid with dyslipidemia and hyperglycemia. However, whether metabolic-modifying agents aggravate schizophrenia progression remains unclear. We perform a drug-target genetic association study in two independent Han Chinese schizophrenia cohorts (N = 2,111/292 for discovery/validation). Leveraging metabolic genome-wide association studies, we generate genetic risk scores (GRSs) for lipid-modifying and hypoglycemic targets. Those with higher APOC3 (inhibited by volanesorsen/olezarsen) GRS exhibit attenuated triglycerides and improvement in negative symptoms assessed by Positive and Negative Syndrome Scale (PANSS) (β = 1.23, 95% confidence interval [CI]: 0.30-2.16). Higher GCK (activated by dorzagliatin) GRS is associated with decreased glucose and less improvement across PANSS total (β = -1.70, 95% CI: -2.91-0.50), positive, negative, general subscales. Causal associations of GCK are replicated in independent validation. The effects of APOC3 and GCK on negative symptom recovery are robust in hyperlipidemic/diabetic subgroups. Genetically proxied proteomics analysis provides further functional validation for the identified target-outcome associations. Our findings suggest volanesorsen/olezarsen as potential adjunctive candidates; dorzagliatin warrants prudence in schizophrenia with metabolic disturbance.

01 Feb 2026·DIABETOLOGIA

Modelling the effects of human SUR1 R1420H variation on insulin secretory function using isogenic iPSC-derived pancreatic islets

Article

Author: Baier, Leslie J ; Bogardus, Clifton ; Barkho, Katiya ; Traurig, Michael ; Cheranda, Koushik Ponnanna ; Nair, Anup K ; Sutherland, Jeffrey R ; Anup, Divya

Abstract:

Aims/hypothesis:

An R1420H variation in sulfonylurea receptor 1 (SUR1), a subunit of the K ATP channel, was previously identified in an Indigenous community in Arizona where a homozygous carrier (1420HH) had hyperinsulinaemic hypoglycaemia during infancy (HHI), suggestive of a K ATP channel loss of function (LoF). Interestingly, heterozygous carriers of this variation (1420RH, occurring in 3% of the community), had a twofold increased risk of type 2 diabetes. We aimed to create an isogenic induced pluripotent stem cell (iPSC)-derived pancreatic islet (SC-islet)-based platform to test whether the R1420H variant results in K ATP channel LoF, and to examine the distinct temporal effects of SUR1 1420HH and 1420RH K ATP channel variations on insulin secretion from developing and mature SC-islets.

Methods:

Using CRISPR-Cas9, isogenic iPSCs with all three genotypes (SUR1 1420RR, 1420RH and 1420HH) were generated from two different parental Indigenous American iPSC lines (IS1, isogenic cell lines derived from parental cell line 1; and IS2, isogenic cell lines derived from parental cell line 2). These isogenic cell lines were used to generate immature SC-islets (resembling fetal islets) and mature SC-islets (resembling adult islets), which were used to assess insulin secretion dynamics during different stages of development and identify differences in gene expression by single-cell RNA-seq. This study was consistent with the CONSIDER statement for research studies among Indigenous American communities.

Results:

Immature SUR1 1420HH SC-islets secreted 3.4-fold (IS1, p <0.001) and 4.2-fold (IS2, p =0.001) more insulin under basal conditions than normal (SUR1 1420RR) SC-islets. Modest hyperinsulinaemia was also seen in immature SUR1 1420RH SC-islets (2.2-fold [IS1] and 2.3-fold [IS2]) but the results were not statistically significant. After maturation, the 1420HH SC-islets failed to achieve glucose responsiveness whereas the 1420RH SC-islets achieved biphasic insulin secretion but had significantly lower glucose responsiveness than normal SC-islets (AUC for insulin secretion [as a % of total insulin] under high glucose challenge: 1.04 vs 0.56 in normal vs 1420RH SC-islets, p <0.001). Diazoxide reduced hyperinsulinaemia in SUR1 1420RH and 1420HH immature SC-islets, while tolbutamide elicited a greatly diminished or undetectable insulin secretory response from mature SUR1 1420RH SC-islets (13.2-fold increase in insulin secretion) and 1420HH SC-islets (1.9-fold increase) compared with normal SC-islets (31.5-fold increase). Results were directionally comparable for both IS1 and IS2 SC-islets. SUR1 1420RH SC-islets also responded to the glucokinase activator dorzagliatin with improvement in first-phase insulin secretory response (first-phase stimulation index: 3.9-fold vs 7.3-fold, p =0.01 [IS1, 11 mmol/l glucose ± dorzagliatin]; 5.5-fold vs 9.0-fold, p =0.13 [IS1, 20 mmol/l glucose ± dorzagliatin]). Single-cell RNA-seq identified dysregulated genes in SUR1 1420RH SC-beta cells, including lower expression of glycolytic genes and upregulation of G6PC2 , which could explain the lower insulin secretory response to glucose.

Conclusions/interpretation:

A SUR1 R1420H variant identified in an Indigenous American population causes hyperinsulinaemia in homozygous immature SC-islets during basal conditions and these SC-islets fail to achieve glucose responsiveness after maturation. In the heterozygous state, modest hyperinsulinaemia is observed in immature SC-islets, which after maturation have significantly lower glucose responsiveness. These results demonstrate that SUR1 R1420H is a K ATP channel LoF variation and suggest that a lower insulin secretory response during adulthood is the cause of the higher type 2 diabetes risk in individuals heterozygous for this variation. We also show that the isogenic iPSC-based platform can be used to test therapeutic agents to treat HHI in infants homozygous for LoF K ATP channels and screen for drugs that can improve glucose-responsive insulin secretion in adult heterozygous carriers.

Data availability:

See the database of Genotypes and Phenotypes (dbGaP; dbgap.ncbi.nlm.nih.gov/home; accession no.: phs002490.v1.p1) for details concerning data requests. All source codes can be found in the GitHub repository under https://github.com/Koushik-Cheranda/SC-islet-scRNAseq-analysis-R-codes .

Graphical Abstract:

News (Medical) associated with Dorzagliatin

22 Jan 2026

·endpoints.news

Hua Medicine plots diabetes drug expansion in China and beyond

Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua’s drug for type 2 diabetes, approved in China under the name Dorzagliatin, does not mimic hormones but instead modulates the body’s biochemical machinery. It enhances the activity of glucokinase, an enzyme that has a broad role in controlling blood sugar. Hua is planning to expand Dorzagliatin beyond mainland China and into Hong Kong, Macau and Southeast Asia. It’s also testing a next-generation version that’s designed to provide more stable glucose control, targeting global expansion. “Hua’s strategy is to demonstrate the broad benefits of addressing the root cause of type 2 diabetes,” chief strategy officer George Lin told Endpoints News during the JP Morgan Healthcare Conference. The company’s next-generation glucokinase activator is being tested in a Phase 1b study in the US. Hua’s goal is to land a pharmaceutical partner that can fund further development aimed at global markets. However, to win such a partnership, it will need to show that the drug works meaningfully better than the original version. Hua believes its drug’s different mechanism could allow it to be used on its own or alongside GLP-1 medicines. In China and surrounding regions, the biotech has set an ambitious sales target, following the end of a key partnership. In late 2024, Hua ended a pact with Bayer, which had been charged with commercializing Dorzagliatin in China. Lin declined to comment on the matter, and Bayer did not respond to an email. Lin said revenue has ramped up after Hua built its own sales force of roughly 200 people. In the first half of 2025, revenue totaled $31.2 million. By 2027, Hua expects to have $143 million in annual revenue. The company also believes that its approach could offer benefits beyond diabetes. Hua plans to study other potentially beneficial effects of its product, including the treatment of mild cognitive impairment and the remission and prevention of diabetes in prediabetes patients.

Phase 1Drug Approval

21 Nov 2024

·www.businesswire.com

Versant Ventures Unveils Pep2Tango Therapeutics Inc.

POTOMAC, Md.--( BUSINESS WIRE )--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. GLP-1-based therapies have proven efficacy in treating obesity and associated co-morbidities, but come with significant drawbacks. These include up to 40% of weight loss from muscle mass reduction, potentially leading to long-term side effects, especially in elderly patients. This limitation, in addition to tolerability issues, reduces the long-term utility of these agents. Pep2Tango’s lead drug candidates are engineered to overcome these drawbacks. They are unimolecular multi-receptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors. This unique combination of targets in one molecule is truly differentiated with key advantages compared with first-generation drugs on the market and therapies currently in development. Preclinical studies of Pep2Tango’s molecules have demonstrated superior weight loss versus tirzepatide, primarily through selective fat mass loss with preservation of muscle mass, improved blood lipid profiles, better glycemic control, and beneficial effects on the liver. The company’s programs were developed by a deeply experienced team led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D. Dr. Rondinone previously was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic diseases at AstraZeneca plc. Prior to that, she held roles of increasing responsibility in cardio-metabolic disease research and development at MedImmune Inc., Roche and Abbott Laboratories, where she led the research and development of multiple molecules that moved to clinical trials including Rezdiffra ™ , dorzagliatin and bentracimab. Dr. Ghosh is a co-founder of multiple biotech companies and served as executive director for research at Amylin Pharmaceuticals Inc., where he was involved in development efforts culminating in the approvals of Byetta ® , Symlin ® , Bydureon ® and Myalept ® . Dr. Ghosh also served as president of the Peptide Therapeutics Foundation. “We are delighted that Versant is backing Pep2Tango as we advance our programs towards clinical development,” said Dr. Rondinone. “There is a critical need to develop safe and highly efficacious drug therapies for obesity that preserve muscle mass and Pep2Tango’s approach should positively impact the lives of patients.” “We are thrilled to partner with the seasoned team of experts at Pep2Tango,” said Carlo Rizzuto, Ph.D., managing director at Versant and a Pep2Tango board member. “We are convinced that the company’s tetra-receptor agonists have best-in-category potential with respect to magnitude and quality of weight loss, as well as improving metabolic and cardiovascular health, that could redefine obesity treatment.” Pep2Tango Therapeutics is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies. An IND submission is expected in 2025. About Pep2Tango Therapeutics Inc. Pep2Tango Therapeutics is a biotechnology company founded in 2021 by seasoned pharmaceutical executives with a long track record of successful drug development. The company’s vision is to develop next generation peptide drugs that target unmet medical needs, including for metabolic, endocrine, CNS and cardiovascular disorders. Pep2Tango’s novel drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for superior weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. The company is backed by Versant Ventures. About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com .

Drug ApprovalIPO

16 Feb 2023

·www.prnewswire.com

111, Inc. Hosts Hua Medicine Launches First Official Flagship Store

SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr. Yu Gang, Co-founder and Executive Chairman of 111, and Dr. Chen Li, Founder and CEO of Hua Medicine (HKEx stock code: 2552.HK), jointly unveiled the plaque of Hua Medicine's first official online flagship store on 111. 111 is committed to digitally connecting patients with medicine and healthcare services, aspiring to build itself into an integrated online and offline healthcare platform. The official flagship store launched by Hua Medicine on 111 will serve as an official window to showcase the outstanding brand image of Hua Medicine and an important platform for Hua Medicine to better serve both patients and doctors. For its part, 111 will further help Hua Medicine expand its commercial layout, broaden its drug supply and distribution channels, and explore innovative and diversified supply service modes. The official flagship store will provide patients with Hua Medicine's innovative treatment concepts, carry out patient education on drug safety and other topics, and release the latest news from Hua Medicine. Dr. Yu Gang, Co-founder and Executive Chairman of 111, said: "Hua Medicine is a leader in innovative drug research and commercialization in China. Over the years, it has devoted itself to the research and development of original drugs. HuaTangNing®, a first-in-class drug of its kind, is from Hua Medicine. The official opening of its flagship store on 111 is a timely and innovative measure taken by a Chinese innovative pharmaceutical company to embrace the Internet. At the same time, it also marks a key milestone for 111 and Hua Medicine in the exploration of online cooperation. 111 will work with Hua Medicine to make cutting-edge innovative drugs more accessible for diabetes patients, empower diabetes treatment as well as patient management, and contribute value to society." Dr. Li Chen, Founder and CEO of Hua Medicine, said: "111 is a benchmark player in China's Internet medicine and healthcare industry, equipped with leading digital technology and smart supply chain. We are very much looking forward to Hua Medicine's cooperation with 111, as we provide innovative solutions of health management and medical services through the online flagship store. In the future, Hua Medicine will continue to explore partnership opportunities with Internet channels to benefit more diabetic patients." About Hua Medicine Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China in September 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: . Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. SOURCE 111, Inc.

100 Deals associated with Dorzagliatin

External Link

KEGG	Wiki	ATC	Drug Bank
D11342	-	-	DB15123

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	China	Hua Medicine (Shanghai) Co., Ltd.	30 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	-	The Chinese University of Hong Kong	01 Aug 2022
Hepatic Insufficiency	Phase 1	China	Hua Medicine (Shanghai) Co., Ltd.	26 Feb 2019
Hyperglycemia	Clinical	Hong Kong	The Chinese University of Hong Kong	02 Apr 2025
Diabetic Nephropathies	IND Application	China	Hua Medicine (Shanghai) Co., Ltd.	-
Frailty Syndrome	Preclinical	China	Hua Medicine Ltd.	27 Mar 2026
Maturity-Onset Diabetes of the Young, Type 2	Preclinical	China	Hua Medicine Ltd.	27 Mar 2026
Mild cognitive disorder	Preclinical	China	Hua Medicine Ltd.	27 Mar 2026
Alzheimer Disease	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Diabetes Mellitus, Type 1	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Metabolic Dysfunction Associated Steatohepatitis	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2026	Not Applicable	Diabetes Mellitus, Type 2	255	Dorzagliatin (TIR≤50%)	arohzaghet(afficzxupu) = ksbbsskkoc gasodperuc (xbjvgvynpp, 1.4) View more	Positive	20 Jun 2026
				Dorzagliatin (50%<TIR≤70%)	arohzaghet(afficzxupu) = bnwsfrbjnf gasodperuc (xbjvgvynpp, 1.0) View more
NCT03790787 (Pubmed \| Nat Commun)	Phase 1	Diabetes Mellitus, Type 2 \| Obesity	16	Dorzagliatin+Empagliflozin	adsxrvcnnn(ycyagjksoe) = gqbrwlbetw bcnnvelzyc (spcmpbvhyi ) View more	Positive	21 Apr 2026
ADA 12025 \| ADA 22025 Manual	Not Applicable	Diabetes Mellitus, Type 2	72	Dorzagliatin	bqidsifadw(wnfklogpzr) = eaezjhlsoa wypyeodtoh (yczohmqtpn ) View more	Positive	20 Jun 2025
DREAM (ADA2022)	Not Applicable	Diabetes Mellitus, Type 2	69	Dorzagliatin	fdahatmjrk(arzpfuwnhl) = oghswvvhqx mslijimfxp (rvdeiqewgz, 53.4 - 77.0)	-	01 Jun 2022
NCT03141073 (DAWN, Pubmed \| Nat Med) Manual	Phase 3	Diabetes Mellitus, Type 2	767	metformin+Dorzagliatin	wakbtggphe(jjjftmllda) = laqyacmbzq ebxlnvmahf (plmfvtqccx, -1.11 to -0.93)	Positive	12 May 2022
				metformin+Placebo	wakbtggphe(jjjftmllda) = lkxqmeimpj ebxlnvmahf (plmfvtqccx, -0.45 to -0.26)
NCT03173391 (SEED, Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	cghyjdlhom(ccwwaeupqs) = lcchjqtuej qztdhtmljz (apufndxgah, -1.19 to -0.95)	Positive	12 May 2022
				Placebo	cghyjdlhom(ccwwaeupqs) = apmfcmlnlf qztdhtmljz (apufndxgah, -0.68 to -0.32)
NCT03141073 (DAWN, ADA2021)	Not Applicable	Diabetes Mellitus, Type 2 Add-on	767	Dorzagliatin	yakszvdyhk(xoqveutzsx) = hrubdumyib lijpbuodvw (pqjzyezppb )	Positive	01 Jun 2021
				Placebo	yakszvdyhk(xoqveutzsx) = tgfrkturwd lijpbuodvw (pqjzyezppb )
NCT03173391 (SEED, ADA2021)	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	lqgtykmffq(jjkiivzdxi) = camighxvjb bfobkirbrz (prnsfakklv ) View more	Positive	01 Jun 2021
				Placebo	hmavpsuxem(zsbsccdtsy) = xuozugogrr pgioldeqej (nipisrzqbt )
NCT03173391 (HMM0301 \| SEED, NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	riweupxgfy(jlqqskiril) = ktoagcowpw qwdjehlwxe (aycrnzrmgi ) View more	Positive	18 Jun 2020
				Placebo	riweupxgfy(jlqqskiril) = snklshuhmi qwdjehlwxe (aycrnzrmgi ) View more
ADA2020	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	yetruysung(jsmhhfkfcu) = qnfqscsjdc dnvivookwt (zxfhqxxwqh ) View more	Positive	01 Jun 2020
				Placebo	huuzyzzgto(xyaceuricy) = amvvxtorik ynnjmhtnde (yleiouecwr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis